Medical Representative - HIV

GSK plans to make up to 500 IT staff in Poznań redundant. The relocation of some IT services from Poznań to India illustrates how quickly global corporations today are reassessing costs, expertise, and the location of their technology infrastructure. September 24, 2026 GSK is planning a major reorganisation of its technical operations in Poznań, with some of the tasks currently carried out there set to be transferred to India. According to information from epoznan.pl, the changes could affect more than 500 IT staff. Hieronim Marut, chairman of the NSZZ "Solidarność" trade union at GSK, confirmed the planned redundancies to the local media. The union has announced that it will enter into negotiations regarding the terms of the redundancies. The decision forms part of a much larger restructuring programme at GSK. In July, the company announced a three-year plan to optimise costs and its organisational structure. By 2029, the company aims to achieve annual savings of £1.9 billion, with restructuring costs estimated at £2.4 billion. GSK highlights, amongst other things, the streamlining of support services, the re-engineering of processes and the wider use of technology and AI. The savings are largely intended to fund investment in research and development and the late stages of new drug development. At the same time, GSK maintains its target of exceeding £40 billion in sales by 2031. For the Polish labour market, however, there is more at stake than just the scale of the redundancies. For years, Poznań has benefited from the growth of global service and technology centres, established in Poland thanks to the wide availability of specialists and relatively competitive costs. Increasingly, this model is being reassessed. Standardised processes can be relocated to cheaper locations, automated or concentrated in a few larger centres. GSK is not alone in this respect. In June, HSBC began restructuring its service centre in Kraków. Eurofound points out that the changes affect, amongst other areas, IT and cybersecurity, and that some processes are also set to be transferred to India. This does not spell the end of Poland's centre of excellence sector, but it may alter its structure. Teams responsible for specialist technologies, architecture, data, cybersecurity and product development are gaining greater value, whilst simpler services that are easier to standardise remain more susceptible to relocation and automation. At the same time, GSK has stated that Poznań will remain one of the company's two multifunctional Global Centres of Competence. However, following the restructuring, the scale of its operations and its employment profile may be significantly different from what they have been to date.

GSK targets £40B sales as oncology push and £1.9B savings plan take shape. GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day. Brown said GSK's strategic portfolio review identified seven major assets across roughly 18 indications for accelerated development, with particular emphasis on oncology. The company also announced a simplification program designed to generate £1.9 billion in savings, with most of the savings intended to fund pipeline investment. Part of the savings is expected to support margins during the period when GSK faces patent expirations for dolutegravir-based HIV medicines. Brown said the company expects margins to be stable to improving from 2028 through 2030, despite the anticipated impact from patent losses. She said GSK has established a track record of investing in research and development while improving productivity, citing expected sales growth above 7%, profit growth above 11% and a margin improvement of more than 500 basis points over the 2021-to-2026 period. Oncology a key difference in revenue expectations. Brown said the largest difference between GSK's outlook of more than £40 billion in sales and consensus estimates of £36.4 billion is in oncology. She cited the company's antibody-drug conjugate portfolio, including assets referred to as MORES and RISRES, as well as BLENREP and Jemperli. She noted that GSK's forecasts include probability-of-technical-and-regulatory-success adjustments. Brown also said consensus may be slower to recognize newer products, including HIV innovations and Excentia. GSK expects specialty medicines to provide a natural lift to profitability as the business mix evolves. Specialty products accounted for just over 40% of the business, compared with roughly one-third when Brown joined in early 2023, and are expected to exceed 50% by 2031, she said. The company is seeking to reduce selling, general and administrative expenses through productivity efforts while increasing R&D investment. Launch dynamics for Excentia and BLENREP. Brown said Excentia, a twice-yearly biologic treatment for severe asthma, has faced a reimbursement and administrative hurdle in the United States because of its upfront cost under the "buy-and-bill" system. The product received a J-code on July 1, but Brown said the related administrative process only began to flow through insurer systems in recent weeks. "We would expect, having removed one of the largest barriers," prescribing conditions to improve entering the fourth quarter, Brown said. GSK plans to provide an update on payer coverage and its patient access program with third-quarter results. For BLENREP, Brown reiterated that GSK intends to "go slow to go big." She said the multiple myeloma treatment has strong clinical data, including a reduction in risk of death and improved progression-free survival, but requires careful monitoring of eye-related side effects. BLENREP is administered as a 30-minute infusion and could address an unmet need among community-treated patients, she said. Outside the U.S., BLENREP has registrations in more than 50 countries and is generally used in the second-line setting, while its U.S. label is for third-line use. Brown said that difference means the U.S. patient population is generally older and frailer, requiring a different launch approach. Hepatitis B and Nuvalent launches. Brown described bepirovirsen as a potentially transformational opportunity in hepatitis B. She said the treatment produced a functional cure in 19% of patients and lowered surface antigen levels in additional patients. GSK has approval in Japan, where pricing negotiations are under way, and expects an approval decision in China around the middle of next year. She identified China, the U.S. and Japan as the main commercial markets for the product. China has an estimated 75 million people affected by hepatitis B, she said, though GSK did not provide country-by-country sales timing or guidance. Brown also highlighted launches from GSK's Nuvalent acquisition. She said idasanlimab had been approved ahead of its PDUFA date and that launch preparations were under way. Niltalisertib, a fourth-generation ALK therapy, has a PDUFA date toward the end of November for an initial second-line indication. GSK expects a potential first-line opportunity to emerge around 2029, with recruitment progressing well in ongoing trials. Headwinds and business development capacity. For 2027, Brown identified TRELEGY as GSK's principal headwind because of pricing implications associated with the Inflation Reduction Act. She said the effect has been incorporated into company forecasts but did not quantify it. She also cited tougher comparisons for products such as SHINGRIX, while noting that vaccination penetration outside the U.S. remains materially below U.S. levels. Brown said GSK continues to evaluate external business-development opportunities alongside internal pipeline programs. Following the Nuvalent acquisition, the company's pro forma net debt-to-EBITDA ratio is just under two times, she said. GSK also expects to generate more than £10 billion in cash from operations this year. Brown said future deal decisions will be based on the quality of an asset rather than whether it is late-stage or early-stage. About GSK (NYSE:GSK). GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world. GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV). The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

Wednesday newspaper round-up: state pension, pharmaceutical companies, BMW. A thinktank linked to Reform UK has called for the abolition of the state pension and £75bn worth of sweeping tax cuts in a "radical" report likely to influence the party's platform for the next election. The Centre for a Better Britain's (CFABB) report - which also calls for weaker rules for UK banks and Trump-style investment accounts offering £1,000 to newborns - will be formally launched at a private event with City executives on Wednesday. - Guardian Motorists buying a secondhand car with a lot of miles on the clock are likely to find an electric vehicle (EV) ultimately more reliable than a petrol vehicle, according to a study. An analysis of 47.4m MOT tests found that after cars were driven 90,000 to 120,000 miles, EVs were about 25% less likely to fail than petrol models of the same age (based on a failure rate of 16.5% versus 22.1%). Beyond 120,000 miles, 16% of EVs failed, compared with 23.5% of petrol cars. The study found relatively little difference between the two fuel types at lower mileages. - Guardian Britain's biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research. AstraZeneca and GSK, along with European rivals Novo Nordisk, Sanofi, Roche and Novartis, wrote an open letter warning that they were "losing ground to global competition". The letter warned that "without urgent action, strategic sectors like pharmaceuticals face a 'slow agony' of decline" as rivals increasingly dominate research-and-development spending and investment. - Telegraph BMW is facing a bill of more than £600m from the motor finance mis-selling scandal, marking one of the biggest hits faced by any lender. In newly filed accounts, the German carmaker's British finance arm increased its provision to cover mis-selling claims from £206m in 2024 to £612m in 2025. BMW's liability is more than the £430m that Barclays expects to pay and the £320m set aside by Close Brothers, another major car finance lender. However, it is still dwarfed by the worst affected lender, Lloyds Banking Group, which has provisioned £1.95bn. - Telegraph The state-backed British Business Bank and NatWest have agreed a "watershed" deal to invest in Phoenix Court, one of the UK's leading venture capital firms. The investment is the latest stage in efforts to get British capital into promising businesses to help them grow. The British Business Bank and NatWest will invest in Phoenix Court funds alongside HSBC and M&G. It is the first time that NatWest has invested in a venture capital fund. HSBC and M&G have invested in previous Phoenix Court funds. - The Times